innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi
Company profile
Ticker
KZIA
Exchange
Website
CEO
James Garner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NOVOGEN LTD
SEC CIK
KZIA stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
1 May 24
6-K
Kazia Reports Successful Stage 1 Completion of the EVT801
1 May 24
424B3
Prospectus supplement
19 Apr 24
6-K
Current report (foreign)
19 Apr 24
424B3
Prospectus supplement
27 Mar 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
26 Mar 24
424B3
Prospectus supplement
21 Feb 24
6-K
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
21 Feb 24
EFFECT
Notice of effectiveness
6 Feb 24
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
PLATINUM INVESTMENT MANAGEMENT LTD
12 Feb 24
SC 13G/A
Novogen LTD
5 Feb 16
SC 13G
Novogen LTD
2 Jul 15
SC 13G/A
Beneficial ownership report (amended)
9 Feb 15
SC 13G/A
Beneficial ownership report (amended)
6 Feb 14
SC 13D/A
Novogen LTD
25 Nov 13
SC 13D/A
Novogen LTD
4 Nov 13
SC 13D/A
Novogen LTD
22 Oct 13
SC 13D/A
AUSTIN JOSIAH T
7 Mar 13
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
12 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
23 Feb 24
What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
21 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
21 Feb 24
Press releases
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
1 May 24
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
21 Mar 24
Kazia announces presentation of new data at AACR Annual Meeting
13 Mar 24
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
26 Feb 24
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
21 Feb 24